-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform, Lowers Price Target to $60

Benzinga·12/03/2025 13:35:48
语音播报
Leerink Partners analyst Joseph Schwartz downgrades BioMarin Pharmaceutical (NASDAQ:BMRN) from Outperform to Market Perform and lowers the price target from $82 to $60.